Treatment of acne vulgaris and prevention of acne scarring: canadian consensus guidelines.
Acne affects approximately 95% of the population at some point during their lifetime.1 This common disorder can range from mild to severe forms, cause sometimes extensive scarring, and can last well into the fourth and fifth decades. Effective therapeutic agents are available to both treat acne and prevent ongoing disease. Despite this, dermatologists frequently see patients with significant acne scarring because many patients delay seeking medical attention for acne and many practitioners procrastinate over using effective antiscarring options. In patients who already demonstrate scarring, repeated courses of antibiotics only result in recurring acne and additional scarring. This, in turn, exacerbates the despair and other adverse psychosocial effects of the disease. There are a variety of agents and devices to help acne patients with scarring. However, successful treatment cannot be guaranteed, and in most cases residual scarring will be evident. Thus, the most effective way of managing acne scarring is to prevent its occurrence in the first place. Although we currently have a number of effective antiacne agents to control the disease, such as antibiotics and hormonal agents, isotretinoina is the only agent that has been shown to induce long-term drug-free remission and curative potential.
Madden
W S
WS
Universtiy of British Columbia, Vancouver, British Columbia, Canada.
Landells
I D
ID
Poulin
Y
Y
Searles
G E
GE
Smith
K C
KC
Tan
J K
JK
Toole
J
J
Zip
C M
CM
Degreef
H
H
D000152:Acne Vulgaris / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D002170:Canada; D002921:Cicatrix / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy; D006801:Humans